DPP4 and Hypoglycemia: On the contrary, reducing glucagon can be achieved safely through incretin mimetics drugs: both dipeptidyl peptidase 4 inhibitors (DPP-4i) and glucagon like peptide 1 analogues (GLP-1a) proved to reduce glucagon levels in a glucose dependent manner, preserving glucagon response to hypoglycemia [28].